<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00412997</url>
  </required_header>
  <id_info>
    <org_study_id>CLBH589B1101</org_study_id>
    <nct_id>NCT00412997</nct_id>
  </id_info>
  <brief_title>LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma</brief_title>
  <official_title>A Phase I Dose-escalation Study of LBH589 Administered Orally in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The phase I study will evaluate the safety, efficacy and pharmacokinetics of LBH589B in adult
      patients with advanced solid tumors or Cutaneous T-cell lymphoma
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum-tolerated dose of LBH589</measure>
    <time_frame>1st cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessed by AEs, SAEs and laboratory values.</measure>
    <time_frame>Every 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic (PK) profile of LBH589</measure>
    <time_frame>every 3 cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess antitumor activity of LBH589</measure>
    <time_frame>every 2 cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Tumors</condition>
  <condition>Cutaneous T-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>LBH589</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LBH589</intervention_name>
    <arm_group_label>LBH589</arm_group_label>
    <other_name>panobinostat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with either a) histologically-confirmed, advanced solid tumors whose disease
             has progressed despite standard therapy or for whom no standard therapy exists, or b)
             cytopathologically confirmed cutaneous T-cell lymphoma (CTCL) whose disease has
             progressed despite standard therapy or for whom no standard therapy exists. Inclusion
             is irrespective of stage of disease or extent of prior therapy.

          -  World Health Organization (WHO) Performance Status of ≤ 2

          -  Patients must have the adequate laboratory values

        Exclusion Criteria:

          -  Patients with a history of primary CNS tumors

          -  Patients with any history of brain metastases

          -  Patients with any peripheral neuropathy ≥ CTCAE grade 2

          -  Patients with unresolved diarrhea ≥ CTCAE grade 2

          -  Impairment of cardiac function

          -  Impairment of gastrointestinal (GI) function or GI disease

          -  Liver or renal disease

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2006</study_first_submitted>
  <study_first_submitted_qc>December 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2006</study_first_posted>
  <last_update_submitted>November 26, 2012</last_update_submitted>
  <last_update_submitted_qc>November 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced solid tumor</keyword>
  <keyword>Cutaneous T-cell lymphoma</keyword>
  <keyword>Phase I</keyword>
  <keyword>HDAC inhibitor</keyword>
  <keyword>Adult patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panobinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

